Skip to main content

Table 5 PCT and the incidence of cancer

From: Plasma procalcitonin is associated with all-cause and cancer mortality in apparently healthy men: a prospective population-based study

Cancer subtype All subjects Men Women
N HRa P b N HRa P c N HRa P c
(95% CI) (95% CI) (95% CI)
Total cancer incidence 520 1.02 (0.93 to 1.12) 0.611 257 1.08 (0.96 to 1.21) 0.184 263 0.97 (0.86 to 1.11) 0.705
Colon 36 1.18 (0.90 to 1.55) 0.238 19 1.49 (1.13 to 1.95) 0.005** 17 0.59 (0.31 to 1.13) 0.108
Rectum 34 1.16 (0.86 to 1.57) 0.343 15 1.14 (0.71 to 1.83) 0.583 19 1.15 (0.79 to 1.67) 0.469
Lung and bronchi 43 0.95 (0.68 to 1.33) 0.764 23 0.95 (0.62 to 1.46) 0.819 20 0.96 (0.59 to 1.54) 0.864
Urinary tract 36 0.87 (0.59 to 1.27) 0.467 22 0.86 (0.55 to 1.35) 0.515 14 0.93 (0.52 to1.68) 0.815
Malignant melanoma 22 1.00 (0.64 to 1.57) 0.999 14 1.17 (0.74 to 1.87) 0.499 8 0.64 (0.26 to 1.62) 0.348
Skin (excluding melanoma) 29 0.88 (0.65 to 1.45) 0.879 19 1.12 (0.74 to 1.70) 0.600 10 0.59 (0.25 to 1.38) 0.225
Prostate     130 1.02 (0.86 to 1.21) 0.841    
Breast        122 1.00 (0.83 to 1.20) 0.998
  1. aExpressed per 1 SD increment. Cox regression analysis adjusted for age and sexb or agec. CI, confidence interval; HR, hazard ratio; PCT, procalcitonin. **P <0.01.
\